Literature DB >> 7535211

Dendritic cells in synovial fluid of chronic inflammatory arthritis lack CD80 surface expression.

K L Summers1, P B Daniel, J L O'Donnell, D N Hart.   

Abstract

Dendritic cells (DC) act as potent primary antigen-presenting cells in many immune responses and therefore may have a role in the initiation and perpetuation of the synovial inflammation in chronic inflammatory arthritis. To examine their function, it is important to isolate fresh DC from arthritic joints without aberrant activation. We have developed a technique using minimal cell manipulation to isolate DC from the synovial fluid of chronic arthritic patients. Using this method, DC were shown to be potent allostimulatory cells, with 63-90% of cells lacking lineage-specific markers (lin-), but positive for MHC class II molecules. Two morphologically distinct populations of these cells were identified in 10 out of 13 DC preparations. Both populations expressed CD40, intercellular adhesion molecule-1 (ICAM-1), ICAM-2, ICAM-3 and leucocyte function associated antigen-3 (LFA-3), but the predominant population, which was larger and more typical of cultured blood DC, had a higher density of these antigens compared with the minor population, which were smaller and morphologically similar to lymphocytes. Two new MoAbs which label activated human blood DC, HB15 (CD83) and CMRF-44, were tested. CD83 labelled very weakly or not at all, whereas CMRF-44 was positive on the larger cells only. Likewise, the costimulator molecule, B7/BB1 (CD80), was not detected on the surface of either synovial lin- cell population, reverse transcriptase polymerase chain reaction (RT-PCR) showed little or no CD80 mRNA, and no binding of the CTLA-4Ig fusion protein was found. These results suggest that synovial DC are not, despite the inflammatory environment, in a fully activated state.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535211      PMCID: PMC1534255          DOI: 10.1111/j.1365-2249.1995.tb03607.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Allostimulatory cells in fresh human blood: heterogeneity in antigen-presenting cell populations.

Authors:  W Egner; R Andreesen; D N Hart
Journal:  Transplantation       Date:  1993-10       Impact factor: 4.939

2.  B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation.

Authors:  D N Hart; G C Starling; V L Calder; N S Fernando
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

3.  Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.

Authors:  V A Boussiotis; G J Freeman; J G Gribben; J Daley; G Gray; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

4.  B70 antigen is a second ligand for CTLA-4 and CD28.

Authors:  M Azuma; D Ito; H Yagita; K Okumura; J H Phillips; L L Lanier; C Somoza
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

5.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

6.  Primary human T-cell responses to the major outer membrane protein of Chlamydia trachomatis.

Authors:  A J Stagg; W A Elsley; M A Pickett; M E Ward; S C Knight
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

7.  Intercellular adhesion molecule-2 (ICAM-2) expression on human dendritic cells.

Authors:  D N Hart; T C Prickett
Journal:  Cell Immunol       Date:  1993-05       Impact factor: 4.868

8.  Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium.

Authors:  U O'Doherty; R M Steinman; M Peng; P U Cameron; S Gezelter; I Kopeloff; W J Swiggard; M Pope; N Bhardwaj
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

9.  Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations.

Authors:  C P Larsen; S C Ritchie; T C Pearson; P S Linsley; R P Lowry
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

10.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.

Authors:  D Hollenbaugh; L S Grosmaire; C D Kullas; N J Chalupny; S Braesch-Andersen; R J Noelle; I Stamenkovic; J A Ledbetter; A Aruffo
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  5 in total

1.  Phenotypic characterization of five dendritic cell subsets in human tonsils.

Authors:  K L Summers; B D Hock; J L McKenzie; D N Hart
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 3.  Antigen-presenting cells in rheumatoid arthritis.

Authors:  R Thomas
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab.

Authors:  Christophe Richez; Thierry Schaeverbeke; Chantal Dumoulin; Joël Dehais; Jean-François Moreau; Patrick Blanco
Journal:  Arthritis Res Ther       Date:  2009-06-29       Impact factor: 5.156

5.  Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis.

Authors:  T R D J Radstake; A B Blom; A W Slöetjes; E O F van Gorselen; G J Pesman; L Engelen; R Torensma; W B van den Berg; C G Figdor; P L E M van Lent; G J Adema; P Barrera
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.